.jpg)
Listen here or where you enjoy podcasts!
With the approval of oral Wegovy making headlines in the new year, it was timely to catch up with Chris on this and many other exciting developments in the realm of GLP-1s. In our main discussion, Chris talks about the immediate impact of oral Wegovy and some small but important differences from its injectable predecessors. He also gets into the application of GLP-1s outside of weight loss, the promise of new agents currently in development, the impact of GLP-1s in corrections healthcare and addresses growing concerns over safety, side-effects, and availability.
For Into the Clinic, Chris shares some important updates involving gonorrhea treatments, functional seizure guidelines, ADA diabetes guidelines, and the GOLD COPD guidelines.
And in our Trivia Capsule segment, we look back at some spectacular failures in the history of weight loss medications and why these drugs did not live up to the weight of expectations.
Sponsor Links:
Reference Links:
Into the Clinic
Second Oral Antibiotic for Gonorrhea Gets FDA Green Light
Novel Oral Antobiotic Matches Standard Option for Urogenital Gonorrhea
FDA Approves New Type of Antibiotic for Gonorrhea, First in Decades
Main Discussion
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Novel GLP-1-Based Medications for Type 2 Diabetes and Obesity
FDA Requests Removal of Suicide Warning on GLP-1s
Trivia Capsule
Evidence from clinical studies of leptin: current and future clinical applications in humans
Music in this episode:
The Retro Synth by Art Haiz
Vitals & Headlines (Suno AI)
Breezy Thoughts (Suno AI)
Trivia Time Ticker (Suno AI)
%20(1).jpg)
